Vol. 17/No. 1 | OncologyLive

PD-1 Success Fuels Interest in Many Immune System Targets

December 28, 2015

It is becoming increasingly clear that PD-1/ PD-L1 and CTLA-4 represent just the tip of the iceberg when it comes to manipulating the immune system to fight cancer, and the number of known checkpoints—and with it the list of potential drug targets—has expanded in recent years.

Importance of BRAF Testing Grows as Options Expand in Melanoma

December 28, 2015

As clinical experience grows with new agents, combinations, and sequences of therapy, the use of molecular profiling in metastatic melanoma is likely to become an essential means of choosing among treatment options.

New Post at MSK Offers Kantoff Another Platform for Leadership in GU Field

December 27, 2015

Philip W. Kantoff, MD, who has made many contributions in prostate cancer research at the laboratory and leadership levels, was honored in the Genitourinary Cancer category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Marking 25 Years of Progress in Blood and Marrow Transplantation

December 25, 2015

While major accomplishments in blood and marrow transplantation (BMT) were being made around the country, the first BMT program at Wake Forest Baptist came into view, a vision brought to life by David D. Hurd, MD.

Can the Breakthrough Therapy Program Transform Cancer Care?

December 23, 2015

In the three years since the FDA launched its breakthrough therapy program, the designation has become a coveted status for emerging agents as biopharmaceutical companies scramble to make their mark in an increasing competitive environment.

Your Go To Source

December 21, 2015

We’re always talking about the rapid pace of oncology drug development in this era, but perhaps nothing illustrates that trend so clearly as the events of one 15-day period in November.

It's Time for True Advances in Comparative Effectiveness Research

December 21, 2015

It is simply unrealistic and highly counterproductive to the future of cancer care to believe that the only acceptable approach to determining the absolute or relative clinical utility of a specific drug, regimen, device, or procedure, is through the conduct of a so-called evidence-based randomized trial.

New Concepts Emerging in Treatment of Advanced Ovarian Cancer

December 16, 2015

Although ovarian cancer remains a formidable challenge in the United States, therapeutic advances achieved during the past several years have provided specialists in gynecologic malignancies with more options than ever for treating patients.